Suicide is the fourth leading cause of death among young people worldwide and the third
leading cause of death among those in the US. This review outlines the epidemiology of …

Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …

Background Previous research has investigated the efficacy of clozapine in reducing
suicidality in patients with schizophrenia and schizoaffective disorder. We aimed to …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Background The antipsychotic, clozapine, is the only licensed drug against the treatment-
resistant symptoms that affect 20–30% of people with schizophrenia. Clozapine is markedly …

Importance Schizophrenia is generally considered to be among the most severe psychiatric
disorders because of the excessive mortality associated with it. Research to find means to …

Executive summary By delivering transformative shifts in societal attitudes and initiating a
radical redesign of mental health care, we can fundamentally improve the lives of people …

Objectives To identify the risks and benefits of clozapine‑lithium co-prescription. Methods
Articles published in English or French were identified with a MEDLINE, Web of Sciences …

In the last decades, the conceptualization of schizophrenia has dramatically changed,
moving from a neurodegenerative process occurring in early adult life to a …

Suicide is a cause of early mortality in nearly 5% of patients with schizophrenia, and 25–
50% of patients with schizophrenia attempt suicide in their lifetime. Evidence points to …